Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
; 2022.
Article
in English
| EuropePMC | ID: covidwho-1756086
ABSTRACT
Objectives:
We aimed to investigate and compare waning vaccine effectiveness (VE) against COVID-19 infection, COVID-19 related ICU admission and COVID-19 related death for BNT162b2 and CoronaVac vaccines.Methods:
We consolidated national data on COVID-19 vaccination and outcomes, and used cases from 1 to 30 September 2021 to compare VE between the ‘early’ (fully vaccinated in April to June 2021) and ‘late’ (July to August 2021) groups. We estimated VE against COVID-19 infection with a negative binomial regression, and VE against ICU admission and death among confirmed COVID-19 cases with a logistic regression.Results:
For BNT162b2, VE against COVID-19 infections declined from 90•8% (95% CI 89•4, 92•1) in the ‘late’ group to 79•3% (95% CI 76•1, 82•1) in the ‘early’ group. VE for BNT162b2 against ICU admission and death were stable. For CoronaVac, VE waned against COVID-19 infections from 74•5% (95% CI 70•6, 78•0) to 30•4% (95% CI 18•8, 40•3). Effectiveness against ICU admission waned from 56•0% (95% CI 51•2, 60•2) to 28•7% (95% CI 12•2, 42•1). CoronaVac's effectiveness against death remained stable.Conclusion:
VE against COVID-19 infection waned after three to five months of full vaccination for both BNT162b2 and CoronaVac vaccines in Malaysia. For CoronaVac, protection against ICU admission also declined.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Vaccines
Language:
English
Journal:
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS